BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today reported data demonstrating the increasing prevalence of essential tremor (ET) from 2010 to 2018; a high rate of depression and anxiety in patients with ET; and the safety and efficacy of Cala Trio when used in a real-world setting […]
Learn About the Cala Trio in Our New Podcast; Take Our Tremor Talk Survey; Scholarship Applications Due October 31.
It’s a watch-like device that stimulates nerves in the wrist to interrupt, and therefore, calm tremors in the hands. Listen to this conversation about the Cala Trio from Cala Health CEO Renee Ryan.
Bioelectronic company Cala Health released positive data from its ongoing PROSPECT trial demonstrating that a majority of patients using its FDA-cleared Cala Trio device reported a reduction in hand tremors.